CTNPT 008: HIV quit smoking pilot study
Counselling programme in combination with nicotine replacement therapy
About the Study
CTNPT 008 looked at the effectiveness of a counselling programme, in combination with nicotine replacement therapy (nicotine patch) to improve quitting rates. The counselling sessions focused on quitting smoking and addressing depression.
Background
The rates of cardiovascular disease (CVD) are high among people living with HIV. Two of the factors thought to contribute to this inflated risk are increased smoking rates and the prevalence of depression in people living with HIV. Smoking is a direct risk factor for CVD and depression makes quitting smoking and remaining smoke-free more difficult. Therefore, the increase in depression and smoking rates may interact to increase the rates of CVD in people living with HIV.
Vel et tristique magna quam. Amet vel ac non nunc. Ut enim, amet, vestibulum lorem id enim elit, feugiat facilisis. Posuere erat eu ut consequat nunc. Amet egestas donec eros amet ultricies mi aliquam. Non eget semper mollis enim scelerisque malesuada eget. Porttitor pretium nibh nibh vitae convallis. Diam at et consequat viverra felis, purus. Et odio mollis facilisis proin cras ullamcorper integer tortor. Sit tincidunt viverra turpis aliquet enim. Quam neque nibh rhoncus tortor. Neque sed dolor aliquet sagittis, malesuada.
Study Approach
Fifty participants were recruited from the Ottawa Hospital. Participants had to be a current smoker, willing to quit within 30 days, diagnosed with HIV, and currently on antiretroviral therapy.
The study used a 24-week counselling design with a 6-month follow up. Counselling sessions occurred at baseline, quit date, and 4, 12, and 24 weeks after quitting. Abstinence from smoking was assessed using self-report questionnaires and biochemical measurement (exhaled carbon monoxide). Psychological and physiological measurements were repeated 6 months following the 24-week counselling period. Study participants were also given telephone-based support throughout the counselling period.
Results
At 6-month follow-up, 28% of participants demonstrated biochemically verified abstinence from smoking. This is considered a successful smoking intervention and compares well to other similar studies. At baseline, 52% of study participants showed signs of clinical depression. At 6-month follow-up, there was a trend towards a decrease in depression. Those with depression were not more likely to relapse back to smoking. This highlights the importance of including depression in counselling sessions to address this barrier to stopping smoking successfully. This pilot trial showed the importance of this type of program to help people with HIV quit smoking.